Atrial fibrillation (AFib) affects approximately 38 million patients globally, significantly increasing the risk of stroke1,2. The Left Atrial Appendage (LAA), a potential source of clot formation, contributes to thromboembolic stroke in patients with non-vascular atrial fibrillation. The investigational Laminar LAA elimination (LAAX) System utilizes rotational motion to eliminate the LAA, aiming to achieve closure with minimal surface area exposure to the left atrial chamber. Laminar was acquired by Johnson & Johnson MedTech in 2023. In March 2024, the company announced the start of enrollment in the pivotal trial evaluating the Laminar LAAX device in the United States.